7:11 PM
Login form
Entries archive

Africa Live News

Main » 2023 » February » 9 » Parse Biosciences Announces Evercode TCR and Gene Capture
11:47 AM
Parse Biosciences Announces Evercode TCR and Gene Capture

New immune profiling and enrichment capabilities expand applications and facilitate scalability

(BUSINESS WIRE) -- (AGBT GENERAL MEETING) — Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the availability of Evercode™ TCR and Gene Capture. These new solutions expand the Parse Biosciences portfolio to address higher scale and immune profiling applications.

Evercode TCR provides researchers the ability to profile T cell receptors (TCR) together with whole transcriptomes in single cells at scale. The diversity of possible TCRs in the immune repertoire is enormous, yet the low throughput of existing tools have limited the ability to capture this complexity at high resolution. Evercode TCR will enable researchers to measure whole transcriptomes and paired TCR sequences - both alpha and beta chains - in up to 1 million cells. Combining TCR sequences with gene expression at this scale makes it possible to track TCR clonotypes across different T cell subtypes and activation states to understand the immune repertoire at exceptional resolution.

Parse also announced the launch of Gene Capture, a solution to reduce sequencing needs for larger studies. Gene Capture focuses sequencing on the most relevant genes, making it possible to efficiently scale projects to millions of cells and hundreds of samples. The solution allows researchers to enrich for 100s-1000s of genes, requiring 10 times less sequencing. Researchers can order a predesigned panel of approximately 1,000 genes relevant to immunology, the Immune1000, or design a panel unique to their needs.

“Increasingly, we see the need to support larger single cell RNA sequencing studies. Biology is complex and requires robust studies across multiple samples, timepoints, and many individual cells to fully capture this complexity,” notes Parse co-founder and CEO Alex Rosenberg, Ph.D. “Parse’s technology has already brought unprecedented scale to the market, and these new tools will expand these capabilities, unlocking new applications in both the research and translational space.”

Charles Roco, Ph.D., Parse co-founder and CTO, will present on the capabilities of Parse’s Evercode TCR and Gene Capture products at the AGBT General Meeting this week at his session, “Broadening Access to Scalable Single Cell Sequencing,” on Wednesday, February 8 at 3:35 pm in the Grand Ballroom.

To learn more about Evercode TCR and Gene Capture Enrichment, please visit

About Parse Biosciences

Parse Biosciences is a Seattle-based company with the mission of accelerating progress in human health and scientific research. At the core of our company is our pioneering approach for single cell sequencing. Single cell sequencing has already enabled groundbreaking discoveries which have led to new understandings of cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. At Parse Biosciences, we are providing researchers with the ability to perform single cell sequencing with unprecedented scale and ease. To learn more, please visit


View source version on

Jay Roberts, SRPR | 917.696.2142

Views: 55 | Added by: africa-live | Rating: 0.0/0
Total comments: 0
Name *:
Email *:
Code *: